Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
VANCOUVER, British Columbia — In patients with refractory or relapsed aggressive lymphoma, immunoradiation combined with high-dose chemotherapy is associated with better progression-free and overall ...
Monjuvi, Revlimid, and Rituxan reduced disease progression risk by 57% in relapsed/refractory follicular lymphoma patients compared to placebo plus Revlimid and Rituxan. The investigational regimen ...
An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial. The regimen, ...
For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those ...
"We found that older age, early relapse, and noncurative treatments were significantly associated with inferior outcomes at a population level." — Inna Y. Gong, MD, PhD, hematologist in the Division ...
Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.
A prognostication tool for early classic Hodgkin's lymphoma outperformed a widely used risk-classification system for predicting 2-year progression-free survival. The model uses four variables: sex, ...
Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results